论文部分内容阅读
目的 :应用免疫组化方法探讨ET 1在蛛网膜下腔出血 (SAH)引起的脑血管痉挛 (CVS)中的作用 ,以及 [D Val2 2 ]大ET 1(16 38)对基底动脉壁ET 1表达的影响和不同用药方式和时机的作用是否相同 .方法 :采用枕大池双注血法制备 36只兔SAH后CVS模型 ,随机分成生理盐水对照组、SAH组、脑池给药预防组、静脉给药预防组、脑池给药治疗组和静脉给药治疗组 .全部实验动物于首次注血后 7d进行灌注固定 ,留取基底动脉和脑组织标本 ,进行免疫组织化学染色 ,观察ET 1的免疫表达 .结果 :ET 1免疫阳性标记颗粒在生理盐水对照组散在不规则表达 ,而在SAH组血管壁各层都有重度表达 .用药预防和治疗组免疫染色强度基本一致 ,血管壁各层的ET 1免疫反应强度介入SAH和对照组之间 .结论 :[D Val2 2 ]大ET 1(16 38)可明显抑制基底动脉壁ET 1的免疫表达 ,无论脑池还是静脉给药均能够达到有效地预防和治疗SAH后CVS .
AIM: To investigate the role of ET 1 in cerebral vasospasm (CVS) induced by subarachnoid hemorrhage (SAH) by immunohistochemistry and the effect of ET 1 (D 1) on ET 1 And the effect of different modes of administration and timing were the same.Methods: Thirty-six CVS models of SAH were prepared by the method of occipital cistern double-injection, then randomly divided into saline control group, SAH group, Administration preventive group, intracisternal administration group and intravenous administration group.All the experimental animals were perfused and fixed 7 days after the first injection of blood, basilar artery and brain tissue samples were taken for immunohistochemical staining, ET 1 Immunofluorescence.Results: Immunofluorescence staining of ET 1 immunopositive particles in the normal saline control group scattered irregularly, but SAH group in each layer of blood vessel wall are heavily expressed.Pharmaceutical immunotherapy and prevention group immunostaining intensity is basically the same, The level of ET 1 immunoreactivity was intervened between SAH group and control group.Conclusion: [D Val2 2], large ET 1 (16 38), could significantly inhibit the expression of ET 1 in basilar artery wall, and could be effective both in cisternal and intravenous administration Pre-ground And after treatment SAH CVS.